Acrux Receives $550K R&D Advance for HRT Development After FDA Pathway Confirmed
Acrux secures $0.55 million R&D tax incentive advance to fund HRT development
Acrux Limited (ASX: ACR) has received a second R&D Tax Incentive Advance totalling $0.55 million under its FY26 funding facility with Radium Capital. The advance covers R&D expenditure from 1 October 2025 to 28 February 2026, representing approximately 80% of the estimated R&D Tax Incentive (RDTI) for the four-month period. Funds will support the progression of development products following the US Food and Drug Administration’s (FDA) confirmation of Acrux’s Hormone Replacement Therapy (HRT) regulatory pathway.
The advance provides near-term working capital without shareholder dilution, enabling the specialty pharma company to maintain development momentum while awaiting full RDTI processing from the Australian Taxation Office.
When big ASX news breaks, our subscribers know first
How R&D tax incentive advances work for ASX biotechs
The RDTI scheme allows eligible Australian companies to claim a refundable tax offset on qualifying research and development expenditure. Rather than waiting until after the financial year ends to receive the rebate, facilities like Radium Capital enable companies to access these funds closer to the period of actual expenditure.
This mechanism functions as a short-term funding facility, not a grant or capital raise.
RDTI advance mechanics:
- Company incurs eligible R&D expenditure
- Facility provider advances approximately 80% of estimated rebate
- Company repays when the ATO processes the full RDTI claim post-financial year
The structure improves cash flow timing for R&D-intensive companies, allowing continuous development activity while minimising the gap between expenditure and reimbursement.
The next major ASX story will hit our subscribers first
HRT programme momentum following FDA pathway confirmation
The funding announcement follows the FDA’s confirmation of Acrux’s HRT regulatory pathway, a development that provides clarity on the commercial route for the company’s hormone replacement therapy products.
“Following the US Food and Drug Administration’s (FDA) confirmation of Acrux’s Hormone Replacement Therapy (HRT) regulatory pathway, funds will be used to support the progression of development products and management of working capital.”
Acrux has built a 25-year track record in developing and commercialising topically applied pharmaceutical products. The company has successfully marketed multiple products worldwide through licensees, with particular emphasis on the United States market. The FDA pathway confirmation de-risks the development timeline by establishing regulatory requirements, while the RDTI advance ensures funding continuity during this critical progression phase.
Consistent facility terms signal stable funding arrangements
The terms of this second advance remain unchanged from the first advance announced on 13 November 2025, demonstrating a consistent, established funding arrangement between Acrux and Radium Capital.
The stability in facility terms suggests a reliable ongoing mechanism for managing R&D cash flow throughout FY26, with the company able to draw down advances as eligible expenditure is incurred rather than relying on lump-sum capital raisings or debt facilities.
For investors, the advance represents routine working capital management rather than a material funding event. However, it confirms active R&D expenditure aligned with the company’s HRT development programme and provides transparency on how Acrux is financing its progression activities following the FDA pathway confirmation.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop, so you’re never behind the curve.